Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale. Its news flow centers on Symvess, an FDA-approved acellular tissue engineered vessel (ATEV™) for extremity arterial injury when autologous vein graft is not feasible, and on the broader clinical and regulatory progress of its ATEV pipeline.
On this page, readers can follow HUMA news related to vascular trauma, hemodialysis access, peripheral artery disease, and other vascular indications where Humacyte’s acellular tissue engineered vessels are being studied. Company announcements frequently cover clinical trial readouts, such as Phase 2/3 and Phase 3 data in trauma and dialysis access, long-term safety and efficacy publications in peer-reviewed journals, and presentations at major medical meetings including the VEITHsymposium and the American Society of Nephrology’s Kidney Week.
Humacyte also issues updates on healthcare economics analyses in extremity arterial injury, highlighting the cost impact of complications like amputation and conduit infection and positioning Symvess as an alternative when vein is not feasible. Additional news items describe humanitarian and real-world use of Symvess in wartime vascular injuries, as well as outcomes in hospital-acquired vascular complications and high-risk patient subgroups.
Investors and clinicians can use this HUMA news feed to track regulatory milestones, such as the FDA approval of the ATEV in vascular trauma, RMAT and Fast Track designations, and planned marketing authorization applications in new territories. Financial and corporate updates, including credit facilities, registered offerings, and sales agreements, are also reported through company press releases and Form 8-K filings. Bookmark this page for an organized view of Humacyte’s latest disclosures on its bioengineered tissue platform, commercial launch activities for Symvess, and ongoing pipeline development.
Humacyte (Nasdaq: HUMA), a biotechnology firm focused on bioengineered human tissue, announced its senior leadership will present at seven significant scientific events in October 2021. CEO Laura Niklason highlighted the advancements in their human acellular vessel (HAV) project, noting its potential across various medical applications. Presentations will cover topics from lung regeneration to vascular access, showcasing the clinical progress of HAV, which is already in Phase 3 trials and has been implanted in over 460 patients. The company aims to connect with industry leaders to discuss pivotal findings and innovations.
Humacyte, Inc. (Nasdaq: HUMA) announced the issuance of three new U.S. patents, enhancing its proprietary technology platform for Human Acellular Vessels (HAVs). These patents include innovative methods for producing HAVs essential for vascular repair and other applications. The comprehensive patent portfolio now includes 119 patents worldwide, with 14 U.S. patents and 105 international patents, providing protection until at least 2035. HAVs, aimed at addressing vessel repair limitations, are undergoing late-stage clinical trials and have shown promising results in over 460 patient implantations.
Humacyte, a clinical-stage biotechnology company (Nasdaq: HUMA), announced participation in five scientific events in September 2021 to present data on their engineered off-the-shelf human acellular vessel (HAV). CEO Laura Niklason emphasized the potential of HAV in various applications, highlighted by presentations on long-term durability in dialysis and its use in vascular repair and pancreatic islet transplantation. The HAV has been used in over 460 implants and is undergoing two Phase 3 trials, showcasing its promise as a revolutionary treatment option.